SKPD / SK Bio - LARVOL DELTA

A novel small molecule gcase activator for Parkinson's disease: Mechanistic insight and broad disease-modifying potential (WPC 2026) - "Taken together, SKPD represents a promising preclinical candidate targeting a fundamental pathological mechanism that is applicable to both GBA1 PD patients and idiopathic PD patients. IND-enabling studies are underway with the goal of submitting an IND application by the second half of 2026."

CNS Disorders • Movement Disorders • Parkinson's Disease • GBA • GBA1

SK biopharmaceuticals’ Parkinson’s drug restores movement, clears toxic protein in early study (Korea Biomedical Review) - "In preclinical models of GBA1-linked Parkinson’s disease, a genetic subset accounting for up to 15 percent of cases of the disease, SK biopharmaceuticals’ oral candidate SKPD restored motor function and maintained its effect for up to three months after treatment ended, the company reported last week....SK biopharmaceuticals said SKPD reduced alpha-synuclein levels in multiple animal models and also activated lysosomal and autophagy pathways, the brain’s internal systems for clearing damaged proteins and cellular debris."

Preclinical • Parkinson's Disease